(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1709467

呼吸器合胞体ウイルス治療薬の世界市場：治療薬の種類別・剤形別・年齢層別・流通チャネル別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Respiratory Syncytial Virus Therapeutics Market, By Treatment Type, By Dosage Form, By Age Group, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 299 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.05円
呼吸器合胞体ウイルス治療薬の世界市場：治療薬の種類別・剤形別・年齢層別・流通チャネル別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 299 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

呼吸器合胞体ウイルス治療薬の市場規模は2024年に15億9,032万米ドルとなり、2025年から2032年にかけてCAGR 15.50％で拡大。

診断技術の進歩が早期発見とタイムリーな介入をサポート北米と欧州は、強力な医療インフラと高い認知度により優位を占めていますが、新興国では導入が拡大しています。市場の成長は、バイオテクノロジー企業と医療機関の共同研究によってさらに支えられています。費用対効果の高い治療法の導入により、世界のアクセシビリティの向上が期待され、より良い疾病管理が保証されます。

呼吸器合胞体ウイルス治療薬の市場力学

乳幼児のRSV（呼吸器合胞体ウイルス）予防のための長時間作用型モノクローナル抗体の採用増加

乳幼児のRSV予防のための長時間作用型モノクローナル抗体の採用増加は、RSV治療薬市場の主要な促進要因です。Palivizumabのような従来のモノクローナル抗体は毎月の投与が必要であり、アクセスやコンプライアンスが制限されていました。しかし、ニルセビマブのような新しい長時間作用型抗体は、1回の投与で長期間の予防効果が得られるため、利便性が高く、費用対効果も高いです。政府や医療機関は、RSVによる入院を減らすために、リスクの高い乳児にこれらの治療を積極的に推奨しています。新生児や未熟児におけるRSV感染の負担が大きいことから、予防接種プログラムが拡大されています。さらに、長時間作用型モノクローナル抗体に対する規制当局の承認や資金援助により、先進国市場や新興国市場での利用可能性が高まっています。これらの治療法が日常的な乳幼児ケアに組み込まれるようになるにつれて、市場成長の大きな原動力になると予想されます。

呼吸器合胞体ウイルス治療薬市場：主な考察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2025-2032年）に約15.50%のCAGRで毎年成長すると予測されています。

治療薬の種類別では、モノクローナル抗体が2024年に最大の市場シェアを示すと予測されています。

剤形別では、注射剤が2024年に主要な剤形となりました。

年齢層別では、乳幼児が2024年の主要年齢層です。

流通チャネル別では、2024年には病院・診療所が流通チャネルのトップです。

地域別では、北米が2024年の主要収益源です。

呼吸器合胞体ウイルス治療薬市場：セグメンテーション分析

呼吸器合胞体ウイルス治療薬の世界市場は、治療薬の種類、投与形態、年齢層、流通チャネル、地域に基づいて区分されます。

市場は治療薬の種類によって3つに分類されます：抗ウイルス薬、モノクローナル抗体、ワクチンです。モノクローナル抗体セグメントは、特に乳幼児や高齢者のようなハイリスクグループの重症RSV感染予防に有効であることから、呼吸器合胞体ウイルス（RSV）治療薬市場を独占しています。パリビズマブは何年も前から広く使用されており、ニルセビマブなどの長時間作用型モノクローナル抗体が最近承認されたことで、この分野はさらに強化されました。これらの治療は受動免疫をもたらし、RSVによる入院や合併症を減少させる。RSV感染症の負担が増加していることに加え、脆弱な集団におけるモノクローナル抗体の使用が政府から推奨されていることが、需要を促進しています。製薬会社は、有効性が向上し、作用時間が延長した次世代モノクローナル抗体の開発に投資を続けています。加えて、これらの治療薬の高価格が市場収益に大きく寄与しています。北米と欧州は、強力な医療インフラと償還政策により、採用が進んでいます。新しい抗体製剤が規制当局の承認を受けるにつれて、このセグメントはRSV治療薬市場における優位性を維持すると予想されます。

市場は剤形によって3つのカテゴリーに分類されます：経口剤、注射剤、吸入剤です。主に注射によって投与されるモノクローナル抗体やワクチンが広く使用されているため、注射剤セグメントが呼吸器合胞体ウイルス（RSV）治療薬市場を独占しています。パリビズマブやニルセビマブのようなモノクローナル抗体や、高齢者向けに新たに承認されたRSVワクチンは、効果的な送達のために注射製剤に依存しています。この投与経路は、正確な投与、迅速な吸収、長時間の防御を保証するため、高リスク集団にとって好ましい選択となります。乳幼児や高齢者の間で重症RSV感染症の発生率が上昇していることから、注射による治療法の採用が増加しています。さらに、政府の予防接種プログラムや病院のプロトコールがRSVの注射療法を支持しており、この分野をさらに後押ししています。北米と欧州は、医療インフラが整っており、ワクチン接種率が高いことから、RSV治療薬の注射剤でリードしています。より多くの長時間作用型モノクローナル抗体やRSVワクチンが承認されるにつれて、注射剤セグメントは優位性を維持すると予想されます。

呼吸器合胞体ウイルス治療薬市場：地域別分析

北米が呼吸器合胞体ウイルス（RSV）治療薬市場を独占しているのは、高い認知度、強固な医療インフラ、モノクローナル抗体とワクチンの広範な採用によるものです。米国は、政府による予防接種プログラムの支援や、ニルセビマブや高齢者向けRSVワクチンのような先進的RSV治療薬に対する規制当局の承認により、同地域をリードしています。乳幼児や高齢者におけるRSV関連の入院患者数の増加が、効果的な治療に対する需要を押し上げています。さらに、大手製薬会社は次世代のモノクローナル抗体を導入するための研究開発に投資しています。好意的な償還政策と高い医療支出が、この地域の市場成長をさらに後押ししています。

米国が呼吸器合胞体ウイルス（RSV）治療薬市場で最大のシェアを占めているのは、高度な医療インフラ、高い疾患認知度、政府の強力な支援が背景にあります。CDCとFDAは、高齢者向けのRSVワクチンと乳幼児予防のためのニルセビマブのような長時間作用型モノクローナル抗体を承認しており、普及を後押ししています。RSVに関連した入院患者、特に乳幼児と高齢者の増加が、効果的な治療に対する需要を高めています。政府が支援する予防接種プログラムや償還政策が、市場の成長をさらに後押ししています。さらに、製薬会社は次世代のRSV治療薬を開発するため、研究や臨床試験に多額の投資を行っています。同国の高い医療支出と強固な規制の枠組みは、市場の継続的拡大を確実なものにしています。

呼吸器合胞体ウイルス治療薬市場：競合情勢

呼吸器合胞体ウイルス（RSV）治療薬市場の競合情勢は、激しい研究開発（R&D）努力、戦略的提携、規制当局の承認によって特徴付けられます。主要企業は、モノクローナル抗体、ワクチン、抗ウイルス薬の開発に注力し、RSV感染の負担増に対処しています。市場を独占しているのは、革新的なRSV治療薬を発表または開発中のAstraZeneca、Sanofi、Pfizer、GSK、Modernaです。

ファイザーがRSV抗ウイルス薬開発のためにReViral社を買収したように、主な企業は戦略的提携や買収を活用して製品ポートフォリオを拡大しています。ニルセビマブのような長時間作用型モノクローナル抗体や高齢者向けRSVワクチンが承認され、競争が激化しています。各社は市場での地位を強化するため、臨床試験、政府との提携、価格戦略にも注力しています。RSVの予防と治療に対する需要の増加に伴い、競合情勢は新規参入企業や先進的な治療ソリューションによって進化していくと予想されます。

目次

第1章 呼吸器合胞体ウイルス治療薬市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 呼吸器合胞体ウイルス治療薬の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 呼吸器合胞体ウイルス治療薬市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 呼吸器合胞体ウイルス治療薬市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 呼吸器合胞体ウイルス治療薬の市場情勢

  • 呼吸器合胞体ウイルス治療薬の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 呼吸器合胞体ウイルス治療薬市場：治療薬の種類別

  • 概要
    • セグメント別シェア分析：治療薬の種類別
    • 抗ウイルス薬
    • モノクローナル抗体
    • ワクチン

第8章 呼吸器合胞体ウイルス治療薬市場：剤形別

  • 概要
    • セグメント別シェア分析：剤形別
    • 経口剤
    • 注射剤
    • 吸入剤

第9章 呼吸器合胞体ウイルス治療薬市場：年齢層別

  • 概要
    • セグメント別シェア分析：年齢層別
    • 乳幼児
    • 大人
    • 高齢者（65歳以上）

第10章 呼吸器合胞体ウイルス治療薬市場：流通チャネル別

  • 概要
    • セグメント別シェア分析：流通チャネル別
    • 病院・診療所
    • 小売薬局
    • オンライン薬局

第11章 呼吸器合胞体ウイルス治療薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ（MEA）
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析：呼吸器合胞体ウイルス治療薬業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • AstraZeneca plc
    • Sanofi SA
    • Pfizer Inc.
    • Moderna, Inc.
    • GSK plc
    • Merck & Co., Inc.
    • Johnson &Johnson
    • Novavax, Inc.
    • Bavarian Nordic A/S
    • Enanta Pharmaceuticals, Inc.
    • BioNTech SE
    • Meissa Vaccines, Inc.
    • Codagenix, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Vaxart, Inc.
    • Icosavax, Inc.

第13章 AnalystViewの全方位的分析

目次
Product Code: ANV4937

REPORT HIGHLIGHT

Respiratory Syncytial Virus Therapeutics Market size was valued at US$ 1,590.32 Million in 2024, expanding at a CAGR of 15.50% from 2025 to 2032.

The Respiratory Syncytial Virus (RSV) therapeutics market focuses on treatments and preventive solutions for RSV infections, which primarily affect infants, older adults, and immunocompromised individuals. This market includes antiviral drugs, monoclonal antibodies, and vaccines aimed at reducing disease severity and transmission. The increasing prevalence of RSV, along with rising hospitalizations, has driven demand for effective therapies. Governments and pharmaceutical companies are investing in research to develop advanced treatments, including long-acting monoclonal antibodies and novel antivirals. Regulatory approvals for RSV vaccines, especially for high-risk groups, have expanded the market.

Advancements in diagnostic techniques support early detection and timely intervention. North America and Europe dominate due to strong healthcare infrastructure and high awareness while emerging economies show growing adoption. Market growth is further supported by collaborations between biotech firms and healthcare organizations. The introduction of cost-effective therapies is expected to enhance accessibility worldwide, ensuring better disease management.

Respiratory Syncytial Virus Therapeutics Market- Market Dynamics

Increasing adoption of long-acting monoclonal antibodies for infant RSV protection.

The increasing adoption of long-acting monoclonal antibodies for infant RSV protection is a key driver of the RSV therapeutics market. Traditional monoclonal antibodies, such as Palivizumab, required monthly dosing, limiting their accessibility and compliance. However, newer long-acting antibodies like Nirsevimab offer extended protection with a single dose, making them more convenient and cost-effective. Governments and healthcare organizations are actively recommending these therapies for high-risk infants to reduce RSV-related hospitalizations. The high burden of RSV infections in newborns and premature babies has led to expanded immunization programs. Additionally, regulatory approvals and funding for long-acting monoclonal antibodies are increasing their availability in developed and emerging markets. As these therapies become more integrated into routine infant care, they are expected to drive market growth significantly.

Respiratory Syncytial Virus Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.50% over the forecast period (2025-2032)

Based on Treatment Type segmentation, monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Dosage Form segmentation, injectable was the leading Dosage Form in 2024

Based on Age Group segmentation, Infants & Young Children was the leading Age Group in 2024

Based on Distribution Channel segmentation, Hospitals & Clinics was the leading Distribution Channel in 2024

based on region, North America was the leading revenue generator in 2024

Respiratory Syncytial Virus Therapeutics Market- Segmentation Analysis:

The Global Respiratory Syncytial Virus Therapeutics Market is segmented based on Treatment Type, Dosage Form, Age Group, Distribution Channel, and Region.

The market is divided into three categories based on Treatment Type: Antiviral Drugs, Monoclonal Antibodies, and Vaccines. The monoclonal antibodies segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to their effectiveness in preventing severe RSV infections, especially in high-risk groups like infants and older adults. Palivizumab has been widely used for years, and the recent approval of long-acting monoclonal antibodies such as Nirsevimab has further strengthened this segment. These treatments provide passive immunity, reducing RSV-related hospitalizations and complications. The increasing burden of RSV infections, along with government recommendations for monoclonal antibody use in vulnerable populations, has fueled demand. Pharmaceutical companies continue to invest in developing next-generation monoclonal antibodies with improved efficacy and longer duration of action. Additionally, the high cost of these therapies contributes significantly to market revenue. North America and Europe lead in adoption due to strong healthcare infrastructure and reimbursement policies. As new antibody formulations receive regulatory approvals, this segment is expected to maintain its dominance in the RSV therapeutics market.

The market is divided into three categories based on Dosage Form: Oral, Injectable, and Inhalation. The injectable segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to the widespread use of monoclonal antibodies and vaccines, which are primarily administered via injection. Monoclonal antibodies like Palivizumab and Nirsevimab, as well as newly approved RSV vaccines for older adults, rely on injectable formulations for effective delivery. This route ensures precise dosing, rapid absorption, and prolonged protection, making it the preferred choice for high-risk populations. The rising incidence of severe RSV infections among infants and older adults has led to increased adoption of injectable treatments. Additionally, government immunization programs and hospital protocols favor injectable RSV therapies, further boosting this segment. North America and Europe lead in injectable RSV therapeutics due to strong healthcare infrastructure and high vaccine coverage. As more long-acting monoclonal antibodies and RSV vaccines gain approval, the injectable segment is expected to maintain its dominance.

Respiratory Syncytial Virus Therapeutics Market- Geographical Insights

North America dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to high awareness, strong healthcare infrastructure, and widespread adoption of monoclonal antibodies and vaccines. The U.S. leads the region, with government-backed immunization programs and regulatory approvals for advanced RSV therapies like Nirsevimab and RSV vaccines for older adults. Increasing RSV-related hospitalizations among infants and elderly populations have driven demand for effective treatments. Additionally, major pharmaceutical companies are investing in research and development to introduce next-generation monoclonal antibodies. Favorable reimbursement policies and high healthcare spending further support market growth in the region.

The United States holds the largest share of the Respiratory Syncytial Virus (RSV) therapeutics market due to its advanced healthcare infrastructure, high disease awareness, and strong government support. The CDC and FDA have approved RSV vaccines for older adults and long-acting monoclonal antibodies like Nirsevimab for infant protection, driving widespread adoption. Rising RSV-related hospitalizations, particularly among infants and the elderly, have increased demand for effective treatments. Government-backed immunization programs and reimbursement policies further boost market growth. Additionally, pharmaceutical companies are heavily investing in research and clinical trials to develop next-generation RSV therapeutics. The country's high healthcare spending and robust regulatory framework ensure continued market expansion.

Respiratory Syncytial Virus Therapeutics Market- Competitive Landscape:

The competitive landscape of the Respiratory Syncytial Virus (RSV) therapeutics market is characterized by intense research and development (R&D) efforts, strategic collaborations, and regulatory approvals. Leading pharmaceutical companies focus on developing monoclonal antibodies, vaccines, and antiviral drugs to address the growing burden of RSV infections. The market is dominated by AstraZeneca, Sanofi, Pfizer, GSK, and Moderna, which have introduced or are developing innovative RSV therapeutics.

Key players are leveraging strategic partnerships and acquisitions to expand their product portfolios, as seen in Pfizer's acquisition of ReViral for RSV antiviral development. The approval of long-acting monoclonal antibodies like Nirsevimab and RSV vaccines for older adults has intensified competition. Companies are also focusing on clinical trials, government collaborations, and pricing strategies to strengthen their market position. With increasing demand for RSV prevention and treatment, the competitive landscape is expected to evolve with new entrants and advanced therapeutic solutions.

Recent Developments:

In February 2024, GSK plc announced that the U.S. Food and Drug Administration (FDA) granted priority review for an application to expand the indication of its combined respiratory syncytial virus (RSV) vaccine to individuals aged 50 to 59 at higher risk of RSV illness.

In May 2023, Pfizer Inc. stated that the U.S. Food and Drug Administration (FDA) approved ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract illness caused by RSV in individuals aged 60 and older. This strategy has contributed to the company's revenue growth.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • Sanofi S.A.
  • Pfizer Inc.
  • Moderna, Inc.
  • GSK plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Novavax, Inc.
  • Bavarian Nordic A/S
  • Enanta Pharmaceuticals, Inc.
  • BioNTech SE
  • Meissa Vaccines, Inc.
  • Codagenix, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Vaxart, Inc.
  • Icosavax, Inc.

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antiviral Drugs
  • Monoclonal Antibodies
  • Vaccines

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Inhalation

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Infants & Young Children
  • Adults
  • Older Adults (65+ years)

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Respiratory Syncytial Virus Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Respiratory Syncytial Virus Therapeutics Market Snippet by Treatment Type
    • 2.1.2. Respiratory Syncytial Virus Therapeutics Market Snippet by Dosage Form
    • 2.1.3. Respiratory Syncytial Virus Therapeutics Market Snippet by Age Group
    • 2.1.4. Respiratory Syncytial Virus Therapeutics Market Snippet by Distribution Channel
    • 2.1.5. Respiratory Syncytial Virus Therapeutics Market Snippet by Country
    • 2.1.6. Respiratory Syncytial Virus Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Respiratory Syncytial Virus Therapeutics Key Market Trends

  • 3.1. Respiratory Syncytial Virus Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Respiratory Syncytial Virus Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Respiratory Syncytial Virus Therapeutics Market Opportunities
  • 3.4. Respiratory Syncytial Virus Therapeutics Market Future Trends

4. Respiratory Syncytial Virus Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Respiratory Syncytial Virus Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Respiratory Syncytial Virus Therapeutics Market Landscape

  • 6.1. Respiratory Syncytial Virus Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Respiratory Syncytial Virus Therapeutics Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 7.1.2. Antiviral Drugs
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Vaccines

8. Respiratory Syncytial Virus Therapeutics Market - By Dosage Form

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable
    • 8.1.4. Inhalation

9. Respiratory Syncytial Virus Therapeutics Market - By Age Group

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
    • 9.1.2. Infants & Young Children
    • 9.1.3. Adults
    • 9.1.4. Older Adults (65+ years)

10. Respiratory Syncytial Virus Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospitals & Clinics
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Respiratory Syncytial Virus Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. The U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Respiratory Syncytial Virus Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AstraZeneca plc
    • 12.2.2. Sanofi S.A.
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Moderna, Inc.
    • 12.2.5. GSK plc
    • 12.2.6. Merck & Co., Inc.
    • 12.2.7. Johnson & Johnson
    • 12.2.8. Novavax, Inc.
    • 12.2.9. Bavarian Nordic A/S
    • 12.2.10. Enanta Pharmaceuticals, Inc.
    • 12.2.11. BioNTech SE
    • 12.2.12. Meissa Vaccines, Inc.
    • 12.2.13. Codagenix, Inc.
    • 12.2.14. Alnylam Pharmaceuticals, Inc.
    • 12.2.15. Vaxart, Inc.
    • 12.2.16. Icosavax, Inc.

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us